Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells Publisher Pubmed

Ganjibakhsh M¹ ; Monshizadeh R² ; Nasimian A³ ; Aminishakib P^{2, 4} ; Farzaneh P¹ ; Tavakoli Shiraji S⁵ ; Gharajei A^{6, 7} ; Rahrotaban S² ; Baghaei F⁴ ; Gohari NS¹

Source: Journal of Oral Pathology and Medicine Published:2018

Abstract

Background: In recent decades, anti-angiogenic treatment strategy has been well described in cancer treatment. The anti-angiogenic activity of both bevacizumab and aflibercept has been researched on 10 previously established primary oral squamous cell carcinoma (OSCC) cells of an Iranian population with different levels of purity, in an attempt to find the most effective anti-angiogenic-targeted drug. Methods: To investigate and compare the effect of bevacizumab and aflibercept on vascular endothelial growth factor (VEGF) secretion of 10 primary OSCC cells, cell proliferation and viability were assessed by ELISA and MTT assays. In addition, cell migration was studied using scratch assay. Results: The results showed that VEGF impressively expressed in all primary cancer cells. Although both drugs significantly reduced the secretion of VEGF, the effect of aflibercept was more prominent. Also, bevacizumab-treated cells migration was lower than the control group and the cells treated with aflibercept showed the lowest migration rate compared to bevacizumab and control groups. Conclusion: The anti-angiogenic-targeted drugs, especially Af, might be effective in treatment of patients with OSCC in combination with conventional surgical treatments. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Related Docs

View other Related Docs

1. The Effect of Aflibercept and Arsenic Trioxide on the Proliferation, Migration and Apoptosis of Oral Squamous Cell Carcinoma in Vitro, Molecular Biology Reports (2021)

2. Challenges Facing Antiangiogenesis Therapy: The Significant Role of Hypoxia-Inducible Factor and Met in Development of Resistance to Anti-Vascular Endothelial Growth Factor-Targeted Therapies, Journal of Cellular Physiology (2019)

3. Mir-155, Mir-191, and Mir-494 As Diagnostic Biomarkers for Oral Squamous Cell Carcinoma and the Effects of Avastin on These Biomarkers, Journal of the Korean Association of Oral and Maxillofacial Surgeons (2020)

Experts (# of related papers)

View all Related Experts

Naghmeh Bahrami (2)

Nasim Vousooghi (2)

Other Related Docs

4. Synthesis, Biological Evaluation, and in Silico Study of Novel Coumarin-Quinazoline Analogs As Potential Anti-Angiogenesis Agents, Results in Chemistry (2024)

5. Synthesis, Radiolabeling, and Biodistribution Study of a Novel Dota-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer, Pharmaceutics (2024)

6. Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein, International Journal of Hematology-Oncology and Stem Cell Research (2018)

7. Docosahexaenoic Acid Reverses the Promoting Effects of Breast Tumor Cell-Derived Exosomes on Endothelial Cell Migration and Angiogenesis, Life Sciences (2021)

8. Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy, Journal of Ocular Pharmacology and Therapeutics (2022)

9. Development of a Recombinant Anti-Vegfr2-Epcam Bispecific Antibody to Improve Antiangiogenic Efficiency, Experimental Cell Research (2021)

10. Angiogenesis and Its Targeting in Glioblastoma With Focus on Clinical Approaches, Cell Journal (2022)

11. Emerging Immunologic Approaches As Cancer Anti-Angiogenic Therapies, Clinical and Translational Oncology (2025)

12. Anti-Tumor Activity of Cediranib, a Pan-Vascular Endothelial Growth Factor Receptor Inhibitor, in Pancreatic Ductal Adenocarcinoma Cells, Cellular Oncology (2020)

13. Vascular Endothelial Growth Factor Expression and Vascular Density in Oral Squamous Cell Carcinoma (Oscc): A Study on Clinical and Histopathologic Significance, Medical Journal of the Islamic Republic of Iran (2016)

14. Anti-Angiogenesis Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Properties Under Experimental Model, Clinical and Experimental Pharmacology and Physiology (2018)

15. Drug Repurposing to Identify Potential Fda-Approved Drugs Targeting Three Main Angiogenesis Receptors Through a Deep Learning Framework, Molecular Diversity (2025)

16. Vascular Endothelial Growth Factor (Vegf) Delivery Approaches in Regenerative Medicine, Biomedicine and Pharmacotherapy (2023)

17. Application of Bevacizumab in the Management of Meningiomas: A Systematic Review and Meta-Analysis, Neurosurgical Review (2024)

18. A Double-Edged Sword Effect of Silver Nanoparticles on Angiogenesis in 4T1 Breast Cancer-Bearing Mice, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)

19. Rolipram Optimizes Therapeutic Effect of Bevacizumab by Enhancing Proapoptotic, Antiproliferative Signals in a Glioblastoma Heterotopic Model, Life Sciences (2019)

20. Perifosine Enhances Bevacizumab-Induced Apoptosis and Therapeutic Efficacy by Targeting Pi3k/Akt Pathway in a Glioblastoma Heterotopic Model, Apoptosis (2017)

Style	Citing Format
MLA	Ganjibakhsh M, et al.. "Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells." Journal of Oral Pathology and Medicine, vol. 47, no. 6, 2018, pp. 575-582.
APA	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, Gharajei A, Rahrotaban S, Baghaei F, Gohari NS (2018). Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells. Journal of Oral Pathology and Medicine, 47(6), 575-582.
Chicago	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, Gharajei A, Rahrotaban S, Baghaei F, Gohari NS. "Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells." Journal of Oral Pathology and Medicine 47, no. 6 (2018): 575-582.
Harvard	Ganjibakhsh M et al. (2018) 'Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells', Journal of Oral Pathology and Medicine, 47(6), pp. 575-582.
Vancouver	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, et al.. Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells. Journal of Oral Pathology and Medicine. 2018;47(6):575-582.
BibTex	@article{ author = {Ganjibakhsh M and Monshizadeh R and Nasimian A and Aminishakib P and Farzaneh P and Tavakoli Shiraji S and Gharajei A and Rahrotaban S and Baghaei F and Gohari NS}, title = {Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells}, journal = {Journal of Oral Pathology and Medicine}, volume = {47}, number = {6}, pages = {575-582}, year = {2018} }
RIS	TY - JOUR AU - Ganjibakhsh M AU - Monshizadeh R AU - Nasimian A AU - Aminishakib P AU - Farzaneh P AU - Tavakoli Shiraji S AU - Gharajei A AU - Rahrotaban S AU - Baghaei F AU - Gohari NS TI - Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells JO - Journal of Oral Pathology and Medicine VL - 47 IS - 6 SP - 575 EP - 582 PY - 2018 ER -

Science Communicator Platform

Authors

Abstract